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INTRODUCTION
Thyroid cancer is the most common endocrine malignancy and
its incidence has increased considerably over the past few decades
(1). This Research Topic is devoted to understanding the mol-
ecular mechanism of human thyroid cancer, with an emphasis
on translation to the clinic. The original research papers assem-
bled here probe the pathogenetic pathway from a wide range
of approaches, including: (1) the role of microenvironment in
thyroid cancer, (2) the role of deiodinases and epigenes lead-
ing to thyroid cancer, (3) functional studies of genetic mutations
that shed insights into the etiology and pathogenesis of papillary
thyroid micro-carcinoma or carcinoma (PTC), (4) genome-wide
studies that describe patho-physiological mechanisms for thyroid
cancer, and (5) epidemiological studies of thyroid cancer incidence
and (6) the influence of environmental factors on development of
human PTC.
SCOPE
The articles gathered here reflect a particular interest in the genetic
and epigenetic factors that could affect the thyroid cancer cell and
its microenvironment. In particular, this topic will present pre-
clinical and clinical research addressing the following issues: (i)
identification of specific molecular patterns of thyroid tumori-
genesis and tumor microenvironment, which could suggest new
directions in pharmacotherapy research; (ii) discovery of new
biomarkers to predict response or resistance to drug treatment,
facilitating targeted cancer therapies and patient follow-up after
treatment; (iii) discovery of environmental risk factors that might
affect PTC development; and (iv) evaluation of preclinical mod-
els of human thyroid cancers with regard to their suitability for
testing new drugs and molecule-targeted agents and for studies
of targetable mechanisms of oncogenesis, malignant progression,
and metastatic disease.
Specific areas of investigation in this topic include the follow-
ing as they relate to thyroid cancer: epidemiology and clinical
research; epigenetics in thyroid; personalized medicine in thyroid;
the tumor microenvironment; novel applications of bioinformat-
ics in human thyroid cancer cell lines; molecular characteriza-
tion of thyroid tumors; and use of diagnostic and prognostic
biomarkers.
WHY IS TARGETING THE THYROID CARCINOMA
MICROENVIRONMENT TRANSLATIONAL?
Currently no successful treatment is available for advanced
thyroid cancer, including poorly differentiated (PDTC),
anaplastic/undifferentiated (ATC), and metastatic recur-
rent/persistent differentiated PTC that is not responsive to
radio-iodine therapy.
The past decade of thyroid cancer research has yielded fun-
damental advances with profound translational potential. Iden-
tification of molecular markers, including oncogenes (e.g., the
BRAFV600E mutation), tumor suppressors (e.g., TP53 mutations),
and translocations (e.g., RET/PTC, PAX8/PPARγ), have clari-
fied molecular mechanisms underlying the pathogenesis of thy-
roid cancer. However, correlations between each biomarker and
prognosis/outcome have not yet been determined in a broad
cohort of patients with metastatic thyroid cancer. Currently,
BRAFV600E is the most frequent genetic hallmark of PTC and
has been highlighted as a prognostic biomarker to improve risk
stratification of patients with PTC, including low risk PTC (2–
7). Recently, a retrospective multicenter study has also shown
that the occurrence of the BRAFV600E mutation was signifi-
cantly associated with increased cancer-related mortality among
patients with PTC. However, because mortality in patients with
PTC was low and the association was not independent of PTC
clinico-pathologic features, the role of BRAFV600E as marker
of mortality risk in patients with PTC remains to be deter-
mined (3).
Preclinical studies have shown that PTC carrying the
BRAFV600E mutation are dependent on this oncoprotein for via-
bility; both genetic and pharmacological inhibition of BRAFV600E
expression or activity is associated with thyroid carcinoma regres-
sion and restoration of radio-iodine uptake in vivo in mice
(8). Furthermore, BRAFV600E plays an important role in PTC
progression to ATC through genes fundamental in the regula-
tion of tumor microenvironment by triggering tumor invasion
and metastasis (9). Therefore, testing a patient’s thyroid cancer
for BRAFV600E will yield important information about potential
tumor aggressiveness and inform future use of targeted therapies
with selective BRAFV600E inhibitors. Collectively, these findings
suggest a potential translational application for anti-BRAFV600E
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therapy in clinical trials for patients with thyroid cancers refrac-
tory to radio-iodine treatment and surgically inoperable thyroid
cancers.
BRAFV600E affects the expression of tumor extracellular matrix
(ECM) non-cellular components [e.g., Thrombospondin-1 (TSP-
1), integrins and others] (9) by regulating PTC cell microenviron-
ment communications; indeed, the molecular action of BRAFV600E
appears to affect both the migratory and invasive properties
of the human thyroid cancer cell itself (10), as well as other
cell types of the thyroid tumor microenvironment. Knowledge
about new BRAFV600E-dependent targets (11) may help identify
secreted factors that could serve as novel prognostic biomark-
ers and/or innovative therapeutic strategies in BRAFV600E-positive
human thyroid cancers. For example, tumor-associated lympho-
cytes and high FoxP3(+) regulatory T cell (Treg) frequency in
primary PTC correlates with more aggressive disease (12, 13).
This suggests Treg frequency could be a predictive factor in
PTC and that the suppressive effects of Treg could be consid-
ered in the design of immune-based therapies in PTC. Also,
Ryder et al. found that tumor-associated macrophages (TAMs)
may facilitate thyroid cancer progression (14), showing that the
presence of a high density of TAMs in advanced metastatic thy-
roid cancers correlates with invasion and decreased cancer-related
survival.
In summary, novel therapeutic strategies that target the
metastatic thyroid carcinoma microenvironment (i.e., ECM cel-
lular and non-cellular components) could offer an additional
approach to the treatment of patients with these types of can-
cers. Targeting other cell types in the microenvironment instead
of, or in addition to, the BRAFV600E-positive metastatic thyroid
cancer cell might also minimize anti-BRAFV600E drug resistance
and provide potential additional therapeutic benefits. Determin-
ing the effects of factors in the thyroid tumor microenvironment
will further define the spectrum of molecular mechanisms under-
lying signaling in metastatic thyroid carcinomas. Understanding
the extent to which microenvironment factors participate in the
aberrant behavior of BRAFV600E-positive human metastatic thy-
roid cancer cells will reveal whether the microenvironment is a
promising target for development of new therapies. In summary,
current research suggests that novel therapies directed against
“microenvironment-specific targets” of thyroid carcinoma are a
promising approach and should be developed and tested in pre-
clinical/translational models of human metastatic thyroid cancer
in the near future.
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